All In Biotech

Drug Trial Radar · NCT05269394

Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU)

A Phase II/III Multicenter Randomized, Double-Blind, Placebo-Controlled Platform Trial of Potential Disease Modifying Therapies Utilizing Biomarker, Cognitive, and Clinical Endpoints in Dominantly Inherited Alzheimer's Disease

Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 197 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

197

Actual

Start

Dec 22, 2021

Primary completion

Apr 2028

Study completion Jul 2028

Sponsor

Lead sponsor
Washington University School of MedicineAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Alzheimer's Association; National Institute on Aging (NIA); Accelerating Medicines Partnership (AMP); Eisai Inc.
First posted
Mar 8, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To assess the safety, tolerability, biomarker, cognitive, and clinical efficacy of investigational products in participants with an Alzheimer's disease-causing mutation by determining if treatment with the study drug improves disease-related biomarkers and slows the rate of progression of cognitive or clinical impairment.

Conditions

  • Alzheimers Disease
  • Dementia
  • Alzheimers Disease, Familial

Interventions

  • E2814Drug

    Administered intravenously in a blinded fashion

  • LecanemabDrug

    Administered intravenously

  • Matching Placebo (E2814)Drug

    Placebo administered intravenously in a blinded fashion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The primary end point is the change from Week 24 to Week 104 and Week 208 in tau PET in the Symptomatic Population (Cohort 1).Time frame: Weeks 24, 104, and 208

Locations

31 sites in 15 countries. Site status is shown where the registry gives one.

  • University of Alabama in Birmingham

    Birmingham, Alabama

  • University of California San Diego Medical Center

    La Jolla, California

  • USC Keck School of Medicine

    Los Angeles, California

  • Yale University School of Medicine

    New Haven, Connecticut

  • Emory University

    Atlanta, Georgia

  • Advocate Lutheran General Hospital

    Park Ridge, Illinois

  • Indiana University School of Medicine

    Indianapolis, Indiana

  • Washington University in St. Louis

    St Louis, Missouri

  • University of Pittsburgh

    Pittsburgh, Pennsylvania

  • Butler Hospital

    Providence, Rhode Island

  • Kerwin Research Center,

    Dallas, Texas

  • University of Washington

    Seattle, Washington

  • Instituto de Investigaciones Neurologicas Raul Carrea, FLENI

    Ciudad Autonoma de Buenos Aire, Argentina

  • Neuroscience Research Australia

    Randwick, New South Wales, Australia

  • Alzheimer's Research Australia

    Melbourne, Victoria, Australia

  • Hospital das Clínicas da Faculdade de Medicina da USP

    São Paulo, Brazil

  • CHU de Quebec - Hôpital de l' Enfant Jésus

    Québec, Canada

  • Sunnybrook Health Sciences Centre

    Toronto, Ontario, Canada

  • McGill Center for Studies in Aging

    Verdun, Quebec, Canada

  • Grupo de Neurociencias Sede de la Universidad de Antioquia

    Medellín, Colombia

  • Universitaetsklinikum Tubingen

    Tübingen, Baden-Wurttemberg, Germany

  • LMU-Campus Grosshadern

    Munich, Bavaria, Germany

  • St Vincent's University Hospital

    Dublin, Dublin, Ireland

  • IRCCS Centro San Giovanni di Dio Fatebenefratelli

    Brescia, Italy

  • Azienda Ospedaliera Universitaria Careggi

    Florence, Italy

  • University of Tokyo Hospital

    Bunkyō City, Tokyo-To, Japan

  • Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez

    Mexico City, Mexico City, Mexico

  • Brain Research Center

    Amsterdam, Netherlands

  • University of Puerto Rico, School of Medicine

    San Juan, Puerto Rico, Puerto Rico

  • Hospital Clínic I Provincial de Barcelona

    Barcelona, Barcelona, Spain

  • The National Hospital for Neurology and Neurosurgery

    London, Greater London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.